$REGN Shareholders: Suffer Losses When Regeneron Stock Plummeted 9%? Securities Fraud Class Action Deadline For Investors is September 14
Bleichmar Fonti & Auld LLP announced a class action lawsuit against Regeneron regarding alleged securities fraud tied to its Phase III Fianlimab-Libtayo clinical trial. The firm alleges Regeneron misled investors about the trial's success, citing significant stock drops in April and May 2026, and set a lead plaintiff deadline of September 14.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.